Evidence Hub

A case series of Candidozyma auris in Viet Nam

Pham VP, Ha NX, Nguyen HT, Hoa LNM, Vu DP, Trang VD, Doorn HRV, Thach PN

BMC infectious diseases, 2026

1 citation

Abstract

Candidozyma auris is an emerging health threat, especially in healthcare settings due to its resistance to several classes of antifungals leading to high mortality. In Viet Nam, the burden of this fungal pathogen is unknown because of little available data. In this report, six cases with C. auris isolation between 2023 and 2024 at the National Hospital for Tropical Diseases, a tertiary referral hospital in northern Viet Nam, are described. Our findings highlight the first report of C. auris in the north of Viet Nam and underscore the importance of prevalence surveys in the future.

How strong is the evidence?

Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free